These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26809514)

  • 1. Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.
    Hollak CE; Biegstraaten M; Baumgartner MR; Belmatoug N; Bembi B; Bosch A; Brouwers M; Dekker H; Dobbelaere D; Engelen M; Groenendijk MC; Lachmann R; Langendonk JG; Langeveld M; Linthorst G; Morava E; Poll-The BT; Rahman S; Rubio-Gozalbo ME; Spiekerkoetter U; Treacy E; Wanders R; Zschocke J; Hagendijk R
    Orphanet J Rare Dis; 2016 Jan; 11():7. PubMed ID: 26809514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations.
    Taruscio D; Gentile AE; Evangelista T; Frazzica RG; Bushby K; Montserrat AM
    Blood Transfus; 2014 Apr; 12 Suppl 3(Suppl 3):s621-5. PubMed ID: 24922304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [European Reference Networks : Consequences for healthcare in Germany].
    Graessner H; Schäfer F; Scarpa M; Wagner TOF
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 May; 60(5):537-541. PubMed ID: 28275837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders.
    Parker S
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv9-14. PubMed ID: 25165190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.
    Talarico R; Aguilera S; Alexander T; Amoura Z; Andersen J; Arnaud L; Avcin T; Marsal Barril S; Beretta L; Bombardieri S; Bortoluzzi A; Bouillot C; Bulina I; Burmester GR; Cannizzo S; Cavagna L; Chaigne B; Cornet A; Corti P; Costedoat-Chalumeau N; Dāvidsone Z; Doria A; Fenech C; Ferraris A; Fischer-Betz R; Fonseca JE; Frank C; Gaglioti A; Galetti I; Guimarães V; Hachulla E; Holmner M; Houssiau F; Iaccarino L; Jacobsen S; Limper M; Malfait F; Mariette X; Marinello D; Martin T; Matthews L; Matucci-Cerinic M; Meyer A; Milas-Ahić J; Moinzadeh P; Montecucco C; Mouthon L; Müller-Ladner U; Nagy G; Patarata E; Pileckyte M; Pruunsild C; Rednic S; Romão VC; Schneider M; Scirè CA; Smith V; Sulli A; Tamirou F; Tani C; Taruscio D; Taulaigo AV; Tincani A; Ticciati S; Turchetti G; van Hagen PM; van Laar JM; Viera A; de Vries-Bouwstra JK; Zschocke J; Cutolo M; Mosca M
    Clin Exp Rheumatol; 2022 May; 40 Suppl 134(5):3-11. PubMed ID: 35349419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RarERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks.
    Talarico R; Cannizzo S; Lorenzoni V; Marinello D; Palla I; Pirri S; Ticciati S; Trieste L; Triulzi I; Terol E; Bucher A; Turchetti G
    Orphanet J Rare Dis; 2020 Dec; 15(1):347. PubMed ID: 33317578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [European Reference Networks for rare diseases].
    Vos JR; van Zelst-Stams WAG; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2018; 162():D2376. PubMed ID: 29676715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Together4RD position statement on collaboration between European reference networks and industry.
    Hedley V; Bolz-Johnson M; Hernando I; Kenward R; Nabbout R; Romero C; Schaefer F; Upadhyaya S;
    Orphanet J Rare Dis; 2023 Sep; 18(1):272. PubMed ID: 37670358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [European Reference Network for Rare Hepatological Diseases (ERN RARE-LIVER)].
    Schulz L; Sebode M; Schramm C; Lohse AW
    Internist (Berl); 2021 Apr; 62(4):441-448. PubMed ID: 33687527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Reference networks for rare diseases: what is the conceptual framework?
    Héon-Klin V
    Orphanet J Rare Dis; 2017 Aug; 12(1):137. PubMed ID: 28784158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Reference Networks and Guideline Development and Use: Challenges and Opportunities.
    Morciano C; Laricchiuta P; Taruscio D; Schünemann H
    Public Health Genomics; 2015; 18(5):318-20. PubMed ID: 26227062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wide disparity of clinical genetics services and EU rare disease research funding across Europe.
    Lynch SA; Borg I
    J Community Genet; 2016 Apr; 7(2):119-26. PubMed ID: 26536881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERN BOND: The key European network leveraging diagnosis, research, and treatment for rare bone conditions.
    Casareto L; Appelman-Dijkstra NM; Brandi ML; Chapurlat R; Cormier-Daire V; Hamdy NAT; Heath KE; Horn J; Mantovani G; Mohnike K; Sousa SB; Travessa A; Wekre LL; Zillikens MC; Sangiorgi L;
    Eur J Med Genet; 2024 Apr; 68():104916. PubMed ID: 38296035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
    Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
    Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the European reference networks for rare diseases ready to embrace machine learning? A mixed-methods study.
    Iskrov G; Raycheva R; Kostadinov K; Gillner S; Blankart CR; Gross ES; Gumus G; Mitova E; Stefanov S; Stefanov G; Stefanov R
    Orphanet J Rare Dis; 2024 Jan; 19(1):25. PubMed ID: 38273306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol research and the alcoholic beverage industry: issues, concerns and conflicts of interest.
    Babor TF
    Addiction; 2009 Feb; 104 Suppl 1():34-47. PubMed ID: 19133913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domain-Specific Common Data Elements for Rare Disease Registration: Conceptual Approach of a European Joint Initiative Toward Semantic Interoperability in Rare Disease Research.
    Abaza H; Kadioglu D; Martin S; Papadopoulou A; Dos Santos Vieira B; Schaefer F; Storf H
    JMIR Med Inform; 2022 May; 10(5):e32158. PubMed ID: 35594066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Networking for rare diseases: a necessity for Europe.
    Aymé S; Schmidtke J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Dec; 50(12):1477-83. PubMed ID: 18026888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.